📊 LRMR Key Takeaways
Is Larimar Therapeutics, Inc. (LRMR) a Good Investment?
Larimar is a pre-revenue biotech company with a strong cash position ($177.9M) and low debt, but faces significant execution risk with deteriorating profitability metrics and accelerating cash burn (-$44.6M operating cash flow). The 57.1% YoY decline in diluted EPS combined with zero revenue generation suggests the company has not yet achieved meaningful clinical or commercial milestones, creating material uncertainty despite adequate near-term cash runway.
Larimar is pre-revenue with sharply negative and worsening profitability, including a -$113M operating cash outflow that exceeds its $85M cash balance, implying a short runway and high financing dependence. While leverage is modest and liquidity is acceptable, the absence of revenue and severely negative returns indicate weak near-term fundamentals.
Larimar Therapeutics, Inc. Key Strengths (LRMR)
- Exceptional cash position of $177.9M provides 4+ years of runway at current burn rate
- Conservative balance sheet with minimal debt (Debt/Equity: 0.09x) and strong liquidity ratios (4.29x)
- Low capital expenditure requirements ($91K) indicate asset-light business model
- Adequate liquidity with 2.19x current/quick ratio
- Low leverage (0.19x D/E; $14.5M long-term debt)
- Minimal capex requirements (asset-light)
LRMR Stock Risks: Larimar Therapeutics, Inc. Investment Risks
- Pre-revenue company with zero commercial sales and no clear path to profitability demonstrated in financials
- Accelerating losses evidenced by 57.1% YoY deterioration in diluted EPS and operating losses of $31.1M
- Significant cash burn of $44.6M annually creates urgent need for clinical trial success or strategic milestone achievement
- Pharmaceutical development faces high regulatory approval risk and long development timelines
- Sustained and rising operating losses and negative FCF (-$113M)
- Short cash runway likely requiring dilutive or costly financing
- Severely negative ROE/ROA and interest coverage
Key Metrics to Watch
- Clinical trial progress and FDA milestone achievements
- Quarterly cash burn rate trend and runway extension
- Revenue generation initiation from any product approvals or partnerships
- Operating cash flow and quarterly burn rate
- Cash and equivalents vs. forecast runway
Larimar Therapeutics, Inc. (LRMR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.29x current ratio provides a solid financial cushion.
LRMR Profit Margin, ROE & Profitability Analysis
LRMR vs Healthcare Sector: How Larimar Therapeutics, Inc. Compares
How Larimar Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Larimar Therapeutics, Inc. Stock Overvalued? LRMR Valuation Analysis 2026
Based on fundamental analysis, Larimar Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Larimar Therapeutics, Inc. Balance Sheet: LRMR Debt, Cash & Liquidity
LRMR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Larimar Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.84 indicates the company is currently unprofitable.
LRMR Revenue Growth, EPS Growth & YoY Performance
LRMR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2020 | N/A | -$3.6M | N/A |
| Q3 2019 | N/A | -$12.1M | N/A |
| Q2 2019 | N/A | -$12.1M | N/A |
| Q1 2019 | N/A | -$13.1M | N/A |
| Q3 2018 | N/A | -$12.6M | N/A |
| Q2 2018 | N/A | -$13.3M | N/A |
| Q1 2018 | N/A | -$13.0M | N/A |
| Q3 2017 | N/A | -$12.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Larimar Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
LRMR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Larimar Therapeutics, Inc. (CIK: 0001374690)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LRMR
What is the AI rating for LRMR?
Larimar Therapeutics, Inc. (LRMR) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LRMR's key strengths?
Claude: Exceptional cash position of $177.9M provides 4+ years of runway at current burn rate. Conservative balance sheet with minimal debt (Debt/Equity: 0.09x) and strong liquidity ratios (4.29x). ChatGPT: Adequate liquidity with 2.19x current/quick ratio. Low leverage (0.19x D/E; $14.5M long-term debt).
What are the risks of investing in LRMR?
Claude: Pre-revenue company with zero commercial sales and no clear path to profitability demonstrated in financials. Accelerating losses evidenced by 57.1% YoY deterioration in diluted EPS and operating losses of $31.1M. ChatGPT: Sustained and rising operating losses and negative FCF (-$113M). Short cash runway likely requiring dilutive or costly financing.
What is LRMR's revenue and growth?
Larimar Therapeutics, Inc. reported revenue of $0.0.
Does LRMR pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
Where can I find LRMR SEC filings?
Official SEC filings for Larimar Therapeutics, Inc. (CIK: 0001374690) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LRMR's EPS?
Larimar Therapeutics, Inc. has a diluted EPS of $-1.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is LRMR's fundamental grade?
Based on our AI fundamental analysis in May 2026, Larimar Therapeutics, Inc. has a C grade with 68% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is LRMR stock overvalued or undervalued?
Valuation metrics for LRMR: ROE of -18.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is LRMR's AI grade for 2026?
Our dual AI analysis gives Larimar Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LRMR's free cash flow?
Larimar Therapeutics, Inc.'s operating cash flow is $-44.6M, with capital expenditures of $91.0K.
How does LRMR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -18.7% (avg: 15%), current ratio 4.29 (avg: 2).